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uman Degenerative Valve Disease
s Associated With Up-Regulation of
ow-Density Lipoprotein Receptor-Related
rotein 5 Receptor-Mediated Bone Formation
rank C. Caira, BSC,* Stuart R. Stock, PHD,† Thomas G. Gleason, MD,* Edwin C. McGee, MD,*
ie Huang, SCD,‡ Robert O. Bonow, MD, FACC,* Thomas C. Spelsberg, PHD,§
atrick M. McCarthy, MD, FACC,* Shahbudin H. Rahimtoola, MB, FRCP, DSC, MACC, MACP,
alini M. Rajamannan, MD, FACC*
hicago, Illinois; Rochester, Minnesota; and Los Angeles, California
OBJECTIVES The goal of this research was to define the cellular mechanisms involved in myxomatous
mitral valve disease and calcific aortic valve disease and to redefine the term degenerative valve
disease in terms of an active cellular biology.
BACKGROUND “Degenerative” valvular heart disease is the primary cause of regurgitant and stenotic valvular
lesion in the U.S. However, the signaling pathways are not known. We hypothesize that valve
degeneration occurs due to an osteoblastic differentiation process mediated by the low-density
lipoprotein receptor-related protein 5 (Lrp5) signaling pathway to cause valve thickening.
METHODS We examined human diseased valves: myxomatous mitral valves (n  23), calcified tricuspid
aortic valves (n  27), calcified bicuspid aortic valves (n  23), and control tissue from mitral
and aortic valves (n  40). The valves were examined by reverse transcriptase-polymerase
chain reaction, Western blot, and immunohistochemistry for signaling markers important in
osteoblast differentiation: Sox9 and Cbfa1 (transcription factors for osteoblast differentiation);
Lrp5 and Wnt3 (osteoblast differentiation signaling marker), osteopontin and osteocalcin
(osteoblast endochrondral bone matrix proteins), and proliferating cell nuclear antigen (a
marker of cell proliferation). Cartilage development and bone formation was measured by
Alcian blue stain and Alizarin red stain. Computed Scano MicroCT-40 (Bassersdorf,
Switzerland) analysis measured calcium burden.
RESULTS Low-density lipoprotein receptor-related protein 5, osteocalcin, and other osteochrondro-
genic differentiation markers were increased in the calcified aortic valves by protein and gene
expression (p  0.001). Sox9, Lrp5 receptor, and osteocalcin were increased in myxomatous
mitral valves by protein and gene expression (p  0.001). MicroCT was positive in the
calcified aortic valves and negative in the myxomatous mitral valves.
CONCLUSIONS The mechanism of valvular heart disease involves an endochondral bone process that is
expressed as cartilage in the mitral valves and bone in the aortic valves. Up-regulation of the
Lrp5 pathway may play a role in the mechanism for valvular heart disease. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.040Cardiol 2006;47:1707–12) © 2006 by the American College of Cardiology Foundation
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veart valve “degeneration” is the most common pathologic
alve disease in the U.S. and Europe. The spectrum of
degenerative” valve lesions have traditionally been thought
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niversity Feinberg School of Medicine, Chicago, Illinois; †Institute for Bioengi-
eering and Nanoscience in Advanced Medicine, Northwestern University, Chicago,
llinois; ‡Department of Preventive Medicine, Northwestern University Feinberg
chool of Medicine, Chicago, Illinois; §Department of Molecular Biology and
iochemistry, Mayo Clinic College of Medicine, Rochester, Minnesota; and the
Division of Cardiovascular Medicine, Department of Medicine, LAC  USC
edical Center, Keck School of Medicine at the University of Southern California,
os Angeles, California. This work was completed with the support of an American
eart Association Grant-in-Aid (0350564Z) and a grant from the U.S. National
nstitutes of Health (1K08HL073927-01). Dr. Rajamannan is an inventor on a patent for
he mechanisms of valve degeneration. The data in this manuscript is not present in the
laims of this patent that was issued in 2003. This patent is owned by the Mayo Clinic,
nd Dr. Rajamannan does not receive any financial royalties secondary to development of
his patent.RT-PCR  reverse transcriptase-polymerase chain reation.o
Manuscript received January 6, 2006; revised manuscript received February 9, 2006,
ccepted February 14, 2006.o be due to a passive disease process developing rapidly
ithin the valve leaflets. The most common location of
hese diseased valves is the left side of the heart. Myxoma-
ous mitral valve lesions causing mitral regurgitation are
elieved to be caused by progressive thickening due to
ctivated myofibroblasts (1). Recent evidence suggests that
he aortic valve develops calcification secondary to an
steoblast differentiation pathway (2). Finally, bicuspid
ortic valve valves develop calcification similar to that of
ricuspid aortic stenosis but at an earlier age (3). The
umber of surgical valve replacements and surgical valve
epairs are increasing in the U.S. due to rapidly aging
opulation.
Despite this increase in prevalence and incidence of
alvular heart disease, the signaling pathways in human
alve disease have not been identified. Our laboratory and
thers have recently demonstrated in experimental animal
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Degenerative Valve Disease and Bone Formation April 18, 2006:1707–12odels that bone matrix protein expression in the aortic
alve and vasculature are regulated by the low-density
ipoprotein receptor-related protein 5 (Lrp5) pathway in the
resence of elevated hypercholesterolemia (4,5). The Lrp5,
co-receptor of low-density lipoprotein receptor family, has
een discovered as an important receptor in the activation of
keletal bone formation via binding to the secreted glyco-
rotein Wnt and activating beta-catenin to induce bone
ormation. Therefore, we hypothesized that the underlying
echanism of “degenerative” valve disease is caused by
steogenic differentiation secondary to the activation of the
rp5 receptors in human diseased valve leaflets. To test this
ypothesis we studied diseased mitral valves, calcified tri-
uspid, and bicuspid aortic valves to determine if the Lrp5
ignaling pathway is expressed in these tissues.
ETHODS
uman calcified aortic valves, degenerative mitral valves,
nd control valves. The use of all human tissue was
pproved by the human subject protection offices at the
ayo Clinic (1732-98), and Northwestern University
1041-002). Tissues were collected at the time of surgery.
e obtained human calcified aortic bicuspid valves (n 23,
ean age 48 years, range 36 to 76 years; men  13 and
omen  10) and tricuspid valves from patients (n  27,
ean age 72 years, range 44 to 93 years; men  13 and
omen  14) at the time of surgical valve replacement. We
ompared them to degenerative myxomatous mitral valve
issue in patients over the age of 40 years (n 22, mean age
2 years, range 58 to 85 years; men  11 and women  11)
emoved at the time of surgical valve repair. Normal control
alves were obtained from the time of heart transplantation
n 40, mean age 51 years, range 19 to 56 years; men 26
nd women  14). Upon dissection, tissues were immersed
n formalin for paraffin embedding and frozen at 80°C for
ibonucleic acid and protein analysis. Valves were stained for
alcification with Alizarin red stain and cartilage with
lcian blue stain.
mmunohistochemistry analysis. Immunohistochemistry
or bone matrix markers, cell proliferation, and the Lrp5
athway was performed as previously described (6). Immu-
ostaining of the valves was performed to identify prolifer-
ting cell nuclear antigen (PCNA) (Dako, Carpenteria,
alifornia). The following primary antibodies were used for
nt3/Lrp5 protein expression: anti-Lrp5 (Biovision,
Abbreviations and Acronyms
Lrp5  low-density lipoprotein receptor-related
protein 5
PCNA  proliferating cell nuclear antigen
RNA  ribonucleic acid
RT-PCR  reverse transcriptase-polymerase chain
reactionountain View, California) and anti-Wnt3 (R & D Sys- (ems, Minneapolis, Minnesota). Osteopontin, bone sialo-
rotein and osteocalcin are glycosylated phosphoproteins
mportant in skeletal bone mineralization, and were de-
ected using antibodies obtained from the National Insti-
utes of Health (gift from Dr. Larry Fisher, NIAMS,
ational Institute of Health) (7,8).
estern blot. Western blot analysis was performed as
reviously described (4). Anti-Lrp5 (178 Kda) (catalogue
umber: PAB-10778, Orbigen, San Diego, California),
nti-Osteocalcin (58 Kda) (gift from Dr. Larry Fisher,
IAMS, National Institute of Health), beta-catenin (85
da) (catalogue number: 2264, Spring Bioscience, Free-
ont, California), MAPKinase (42 Kda) (anti-p42/44)
catalogue number: 9106, Cell Signaling Technology, Dan-
ers, Massachusetts) were tested to confirm the activation of
ellular proliferation; anti-alpha actin (42 Kda) (catalogue
umber: M0851 Dako) was used as a control. We per-
ormed (n  4) replicates on each Western blot and reverse
ranscriptase-polymerase chain reaction (RT-PCR) experi-
ent, and show a representative experiment for the data.
emiquantitative RT-PCR. Immediately after dissection
rom the heart, the leaflets from each aortic valve were
rozen in liquid nitrogen for ribonucleic acid (RNA),
xtraction. Total RNA was isolated using Trizol reagent
Invitrogen, Carlsbad, California), and 4 g of RNA were
sed for semiquantitative RT-PCR analysis. Reverse
ranscriptase-polymerase chain reaction was performed to
etermine expression levels of Cbfa1 (289 base pairs [bp]),
ox9 (170 bp), osteocalcin (150 bp), osteopontin (102 bp),
yclin (151 bp), and GAPDH (housekeeping gene) (451 bp)
s previously described (2).
icroCT. After fixing in formalin, the valves were exam-
ned using a Scanco MicroCT-40 system (Bassersdorf,
witzerland) operated at 45 kV. Sampling was with 8 m
oxels (volume elements) and maximum sensitivity (1,000
rojections, 2,048 samples, and 0.3 s/projection integration
2]); n  10 valves total were tested.
tatistics. Data are presented for each diseased valve as an
verage of the percent of the internal control. The internal
ontrol was GAPDH (housekeeping gene) for the polymer-
se chain reaction and actin for the Western blot. We used
ne-way analysis of variance to examine if there are differ-
nces in normalized gene and protein expression among
iseased valves and the control valves, followed by the
unnett’s test to compare the diseased valves to the control
alve with adjustment for the multiple comparisons. Signif-
cance of the test statistics is set at 0.05 level. Table 1 lists
he mean and the standard error for each type of valve
ested.
ESULTS
pecial stains of the human mitral degenerative valves
nd calcified aortic valves for bone and cartilage forma-
ion. Figure 1 demonstrates the stains for calcification
Alizarin red), cartilage (Alcian blue), and MicroCT. Figure
1
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April 18, 2006:1707–12 Degenerative Valve Disease and Bone FormationA (panels A1 and A2) demonstrates a minimal amount of
lizarin red staining mineralizing tissue present in the
ontrol and degenerative mitral valves as compared with the
alcified aortic valves, as shown in Figure 1A (panels A3 and
4). In contrast, Figure 1B (panel B2), the Alcian blue
artilage stain, was more intense in the degenerative mitral
alves in the areas of the hypertrophic chrondrocyte cells
resent in the mitral valves (arrow points to hypertrophic
hrondrocyte cells). Figure 1B (panel B1) demonstrated a
ild amount of cartilage stain in the control valves, and the
alcified aortic valves in Figure 1B (panels B3 and B4)
emonstrated minimal Alcian blue cartilage stain. Figure
C (panels C1 and C2) demonstrates that there was no
alcification in the control and degenerative mitral valves.
he calcified tricuspid and bicuspid aortic valve tissue
emonstrated a large amount of calcification as shown in
igure 1C (panels C3 and C4).
Table 1. Quantitative Analysis of Western Blo
Control
Valve
Dege
Mitra
Western
Lrp5 0.27  0.01 0.58
Osteocalcin 0.60  0.01 0.56
Beta-catenin 0.58  0.01 0.68
p42/44 0.62  0.01 0.57
RT-PCR
Cbfa 1 0.64  0.01 0.82
SOX 9 0.57  0.01 1.02
Cyclin 0.59  0.01 1.09
Osteocalcin 0.39  0.01 1.14
Osteopontin 0.45  0.01 1.10
*Value increase greater than control, p  0.001. †Value dec
RT-PCR  reverse transcriptase-polymerase chain reacti
igure 1. Immunohistochemistry of the human mitral degenerative valves
icroCT scan. Control valve, degenerative mitral valve (arrow points to hynd bicuspid aortic valve (arrow points to positive stain) (magnification 25). (A
s the soft tissue, white area is calcification, blue is the background).mmunohistochemistry of the human mitral degenera-
ive valves and calcified aortic valves for non-collagenous
one matrix synthesis. Figure 2 demonstrates the immu-
ohistochemistry stain for non-collagenous bone matrix
roteins: bone sialoprotein, osteopontin, and osteocalcin.
here was positive bone sialoprotein staining in the control
alves as shown in Figure 2A (panel A1), but this was more
ntense in the areas of hypertrophic chondrocytes present in
he degenerative mitral valves (Fig. 2A, panel A2), as well as
he calcified aortic valves as shown in Figure 2A (panels A3
nd A4). The osteopontin and osteocalcin stains were more
ntense in the calcified aortic valves, as shown in Figures 2B
panels B3 and B4) and 2C (panels C3 and C4), as
ompared with the degenerative mitral valves (Figs. 2B
panel B2] and 2C [panel C2]). The control tissue demon-
trated little evidence of osteopontin and osteocalcin (Figs.
B [panel B1] and 2C [panel C1]).
RT-PCR
ive
ve
Calcified
Aortic Valve
Calcified
Bicuspid Valve
1* 0.94  0.01* 0.60  0.01*
0† 1.20  0.01* 0.69  0.01*
1* 2.29  0.01* 0.70  0.01*
1† 0.86  0.01* 1.02  0.01*
0* 0.82  0.01* 0.43  0.01†
3* 0.80  0.01* 0.85  0.02*
1* 1.15  0.02* 0.54  0.01
4* 1.21  0.03* 0.76  0.01*
2* 0.85  0.01* 0.49  0.01
ess than control, p  0.001.
alcified tricuspid and bicuspid aortic valves for calcification, cartilage, and
ophic chondrocytes), calcified aortic valves (arrow points to positive stain),t and
nerat
l Val
 0.0
 0.0
 0.0
 0.0
 0.0
 0.0
 0.0
 0.0
 0.0and c
pertr) Alizarin red stain. (B) Alcian blue stain. (C) MicroCT scan (gray area
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Degenerative Valve Disease and Bone Formation April 18, 2006:1707–12mmunohistochemistry of the human mitral degenera-
ive valves and calcified aortic valves for endochondral
ignaling markers Lrp5/Wnt and PCNA. Figure 3 dem-
nstrates the immunohistochemistry stains for the osteo-
last signaling markers: Lrp5, Wnt3, and PCNA. Figures
A (panels A1 and A2) and 3B (panels B1 and B2)
emonstrate a mild amount of Lrp5 and Wnt3 staining in
he control valves and in the areas of hypertrophic chon-
rocytes in the mitral valves. The Lrp5 and Wnt3 staining
as increased in the calcified aortic valves (Figs. 3A [panels
3 and A4] and 3B [panels B3 and B4]). Figure 3C, panels
igure 2. Immunohistochemistry of the human mitral degenerative valves a
ynthesis. Control valve, degenerative mitral valve (arrow points to hypertr
icuspid aortic valve (arrow points to positive stain) (magnification 25).
taining (magnification 40). (A) Bone sialoprotein stain. (B) Osteopont
igure 3. Immunohistochemistry of the human mitral degenerative valve
arkers low-density lipoprotein receptor-related protein 5/Wnt and prolife
o hypertrophic chondrocytes), calcified aortic valves (arrow points to positi
5). Insert within each photo is a high-power magnification to demonstrate cel
stain. (B) Wnt 3 stain. (C) Proliferating cell nuclear antigen stain.3 and C4, demonstrates the presence of an increase in
CNA protein expression as compared with Figure 3C,
anels C1 and C2, which demonstrates a decrease in PCNA
rotein staining.
estern blot, semiquantitative RT-PCR, and MicroCT.
igure 4 demonstrates the Western blot analysis for Lrp5,
steocalcin, beta-catenin (downstream co-transcription fac-
or in the Wnt pathway) and p42/44 (a signaling marker of
roliferation) in these valves. Figure 5 demonstrates the
emiquantitative RT-PCR for Cbfa1, Sox9, cyclin, osteo-
alcin, and osteopontin in these valves. Table 1 demon-
lcified tricuspid and bicuspid aortic valves for non-collagenous bone matrix
chondrocytes), calcified aortic valves (arrow points to positive stain), and
within each photo is a high-power magnification to demonstrate cellular
in. (C) Osteocalcin stain.
calcified tricuspid and bicuspid aortic valves for endochondral signaling
cell nuclear antigen. Control valve, degenerative mitral valve (arrow points
n), and bicuspid aortic valve (arrow points to positive stain) (magnificationnd ca
ophics and
rating
ve stailular staining (magnification 40). (A) lipoprotein receptor-related protein
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April 18, 2006:1707–12 Degenerative Valve Disease and Bone Formationtrates the quantification and statistical analysis of the
estern blot and the RT-PCR data. Results from the
unnett’s tests show that using Western blot expression
evels in diseased valves are significantly different than those
n control valves (p  0.001); using polymerase chain
eaction, except for cyclin and osteopontin in bicuspid aortic
alve, expression levels in diseased valves are significantly
ifferent than those in control valves (p  0.001). One
onfounding limitation is the age differences between these
iseased valves as we did not age-match these comparison
tudies.
ISCUSSION
ntil recently the etiology of valvular heart disease has been
hought to be a “degenerative” process related to the passive
ccumulation of calcium binding to the surface of the valve
eaflet. Recent descriptive studies have demonstrated the
ritical features of aortic valve calcification, including osteo-
last expression, cell proliferation, and atherosclerosis
2,6,9,10), and mitral valve degeneration, glycosaminglycan
ccumulation, proteoglycan expression, and abnormal col-
agen expression (11–14). These studies define the bio-
hemical and histologic characterization of these valve
esions.
The most striking phenotypic abnormalities in our study
re the formation of cartilaginous structures in the degen-
rative mitral valves and bone formation in the calcified
ortic valves. At the light microscopy level, we were also able
o identify hypertrophic chrondrocytes in all of the diseased
itral valves that we studied. We further confirmed a
arked increase in Sox9 expression in diseased mitral valves,
hich is a critical transcription factor in the early stage of
artilage differentiation. In the calcified aortic valves, we
ound all of the other markers of bone differentiation
ncluding the non-collagenous bone matrix proteins os-
eopontin, osteocalcin, and bone sialoprotein and the osteo-
last transcription factor Cbfa1, which were increased in the
alcified aortic valves and expressed at a lower level in the
igure 4. Western blot. Western blot analysis for lipoprotein receptor-
elated protein 5 (Lrp5), osteocalcin, -catenin, p42/44, and -actin.egenerative mitral valves.
t
SThis study provides protein, gene, and histologic evidence
f the spectrum of endochrondral ossification similar to the
iology of adult skeleton bone formation. We also tested the
ypothesis that valvular osteoblast differentiation occurs in
arious stages in the mitral valve as compared with the
alcified aortic valve, which is regulated by the Lrp5/Wnt3
athway. We found that the Lrp5/Wnt3 signaling markers
re present in the calcified aortic valve greater than the
egenerative mitral valve. These data provide the first
vidence of a mechanistic pathway for the initiation of bone
ifferentiation in degenerative valve lesions, which is ex-
ressed in the mitral valve as a cartilage phenotype and in
he calcified aortic valve as a bone phenotype. These results
ndicate that there is a continuum of an earlier stage of
steoblast bone differentiation in the mitral valves as com-
ared with the calcified aortic valves. The mitral valves did
ot demonstrate the full osteoblast mineralized phenotype,
ut an early cartilage phenotype with positive Alcian blue
tain and Sox9 expression. In normal adult skeleton forma-
ion, the initiation of bone formation occurs with the
evelopment of a cartilaginous template, which eventually
ineralizes and forms calcified bone. Therefore, the mitral
alve expresses an early cartilage formation, and the aortic
alve demonstrates the mineralized osteoblast phenotype,
hich follows the spectrum of normal skeletal bone forma-
ion. These data demonstrate the significance of the appear-
nce of thickened mitral valves developing cartilage, which
ay play a role in the development of severe regurgitation in
atients who are older than age 40 years and do not have a
lear etiology for the mechanism of mitral valve disease. The
alcified aortic valves express an osteoblast phenotype:
bone” in the aortic valve that is responsible for the stenosis
resent in symptomatic aortic stenosis requiring surgical
alve replacement. Our experimental studies further dem-
igure 5. Semiquantitative reverse transcriptase-polymerase chain reac-
ion. Reverse transcriptase-polymerase chain reaction results for Cbfa1,
ox9, cyclin, osteocalcin, and osteopontin.
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Degenerative Valve Disease and Bone Formation April 18, 2006:1707–12nstrate that hypercholesterolemia may play a role in the
nitiating event in these diseases (6,15,16).
This is the first study to demonstrate the presence of
hondrocytes in mitral valves, and osteoblasts in aortic
alves implicating this pathologic mechanism in the devel-
pment of mitral regurgitation in myxomatous mitral valves
nd stenosis in calcific aortic valves. These findings may be
econdary to an osteoblast differentiation process that is
ediated by the Lrp5/Wnt3 pathway and demonstrating an
ctive endochondral bone formation mechanism in the
evelopment of heart valve disease.
cknowledgment
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tudy.
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